BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26199132)

  • 1. High proliferation index, as determined by immunohistochemical expression of Aurora kinase B and geminin, indicates poor prognosis in neuroblastomas.
    Ramani P; Sowa-Avugrah E; May MT
    Virchows Arch; 2015 Sep; 467(3):319-27. PubMed ID: 26199132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas.
    Ramani P; Nash R; Sowa-Avugrah E; Rogers C
    J Neurooncol; 2015 Oct; 125(1):103-11. PubMed ID: 26318737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aurora kinase A is superior to Ki67 as a prognostic indicator of survival in neuroblastoma.
    Ramani P; Nash R; Rogers CA
    Histopathology; 2015 Feb; 66(3):370-9. PubMed ID: 25297850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas.
    Ramani P; Taylor S; Miller E; Sowa-Avugrah E; May MT
    J Histochem Cytochem; 2015 Jun; 63(6):397-407. PubMed ID: 25711230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group.
    Teshiba R; Kawano S; Wang LL; He L; Naranjo A; London WB; Seeger RC; Gastier-Foster JM; Look AT; Hogarty MD; Cohn SL; Maris JM; Park JR; Shimada H
    Pediatr Dev Pathol; 2014; 17(6):441-9. PubMed ID: 25207821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Relationship Between Apoptotic Activity and Prognostic Factors in Neuroblastomas.
    Ekmekci S; Olgun N; Özer E
    Turk Patoloji Derg; 2016; 32(2):99-104. PubMed ID: 27136108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferation index revisited in neuroblastic tumors.
    Iżycka-Świeszewska E; Lipska-Ziętkiewicz BS; Adamkiewicz-Drożyńska E; Grajkowska W; Hermann B; Bień E; Limon J
    Folia Neuropathol; 2014; 52(3):243-52. PubMed ID: 25310735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
    Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
    Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
    Wang LL; Teshiba R; Ikegaki N; Tang XX; Naranjo A; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Shimada H
    Br J Cancer; 2015 Jun; 113(1):57-63. PubMed ID: 26035700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas.
    Dungwa JV; Hunt LP; Ramani P
    Hum Pathol; 2012 Oct; 43(10):1651-60. PubMed ID: 22436629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Podoplanin lymphatic density and invasion correlate with adverse clinicopathologic and biological factors and survival in neuroblastomas.
    Ramani P; Somerville MS; May MT
    Am J Surg Pathol; 2012 Jun; 36(6):908-15. PubMed ID: 22588067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Shimada H; Umehara S; Monobe Y; Hachitanda Y; Nakagawa A; Goto S; Gerbing RB; Stram DO; Lukens JN; Matthay KK
    Cancer; 2001 Nov; 92(9):2451-61. PubMed ID: 11745303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.
    Shimada H; Stram DO; Chatten J; Joshi VV; Hachitanda Y; Brodeur GM; Lukens JN; Matthay KK; Seeger RC
    J Natl Cancer Inst; 1995 Oct; 87(19):1470-6. PubMed ID: 7674334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIF-1α up-regulation is associated with adverse clinicopathological and biological factors in neuroblastomas.
    Dungwa JV; Hunt LP; Ramani P
    Histopathology; 2012 Sep; 61(3):417-27. PubMed ID: 22571395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implication of unfavorable histology, MYCN amplification and diploidy for stage I and II neuroblastomas.
    de Buys Roessingh AS; Rougemont AL; Wiesenauer C; Barrette S; Bouron-Dal Soglio D; Lallier M
    Eur J Pediatr Surg; 2008 Dec; 18(6):410-4. PubMed ID: 19012235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROX1 lymphatic density correlates with adverse clinicopathological factors, lymph node metastases and survival in neuroblastomas.
    Ramani P; Norton A; Somerville MS; May MT
    J Neurooncol; 2012 Jul; 108(3):375-83. PubMed ID: 22382784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients.
    Verly IRN; van Kuilenburg ABP; Abeling NGGM; Goorden SMI; Fiocco M; Vaz FM; van Noesel MM; Zwaan CM; Kaspers GJL; Merks JHM; Caron HN; Tytgat GAM
    Eur J Cancer; 2018 Feb; 90():102-110. PubMed ID: 29274926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.